(MENAFN- GetNews) (Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Fuchs Dystrophy pipeline constitutes 5+ key companies continuously working towards developing 5+ Fuchs ...

Kids with Duchenne muscular dystrophy and their families deserve the chance to decide their own future.

Roche’s autoimmune drug Enspryng is making solid progress as a treatment for neuromyelitis optica spectrum disorder (NMOSD). But the company’s efforts to expand its use to a new indication is coming ...

With Tammy Baisden devoting most of her life to serving Vermillion with kindness, dedication and a willingness to help others ...

A new series exploring how and why people are living longer—and what this means for the future Women Live Longer—So Why Are They Sicker As They Age? Can Aging Be Measured—and Eventually Reversed? How ...

Nutrition, disease, accidents, physical activity and labor—many of the things that humans do or experience leave traces in ...

PHOENIX — Jace Taylor is a rambunctious 4-year-old boy. He runs, jumps and plays with his friends. He isn’t aware that genetically, he’s different from other children. “I think he’s too young to ...

More than 30 rare muscular dystrophy types cause progressive muscle weakness from inherited gene mutations. Combined, they affect about 1 in 5,000 to 8,000 people. Common subtypes vary by age of onset ...

March 11, 2026 • New research finds AI can point people in the wrong direction. And the quality of health information it imparts depends on how well you prompt the tools. March 10, 2026 • With the ...

German poker pro Tom Fuchs closed out his best year ever on the live tournament poker circuit with his largest victory yet. The friend of CoinPoker defeated a field of 130 entries in the 2024 World ...

Our research program focuses on community-based and population health research. We assist with concept development, study design, quantitative and qualitative evaluations and statistical design, ...

Delandistrogene moxeparvovec demonstrated a manageable safety profile across clinical trials for Duchenne muscular dystrophy (DMD), with most adverse events emerging within 90 days of infusion. Barry ...